Abstract
A greater understanding of the pathogenesis and biology of cancer coupled with major advances in biotechnology has resulted in the identification of rationally designed, target-based (RDTB) anticancer therapeutics, ushering in new therapeutic opportunities and high expectations for the future as well as developmental challenges. Because these agents appear to principally target malignant cells, it is expected that they will produce less toxicity at clinically effective doses than nonspecific cytotoxic agents, but their target requirements are likely to be much more stringent. The innate complexity of the networks that contain elements targeted by these agents also decreases the probability that any single therapeutic manipulation will result in robust clinical activity and success when used alone, particularly in patients with solid malignancies that have multiple relevant signaling aberrations. In contrast, proof of principle and robust antitumor activity may be most efficiently demonstrated in nonrandomized evaluations involving tumors that are principally driven by aberrations of the specific target. The predominant therapeutic manifestation of RDTB agents in preclinical studies is due to decreased tumor growth rates and wil...Continue Reading
References
Apr 13, 1995·The New England Journal of Medicine·E K Rowinsky, R C Donehower
Jun 15, 1997·The Biochemical Journal·C T ChuD D Bigner
Nov 6, 1998·Molecular Pharmacology·H HosoiP J Houghton
Dec 3, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E A Eisenhauer
Sep 1, 1999·European Journal of Biochemistry·A BessonV W Yong
Jan 19, 2000·British Journal of Cancer·E O Olapade-OlaopaF K Habib
Jun 28, 2001·Oncogene·M Hidalgo, E K Rowinsky
Aug 16, 2001·Proceedings of the National Academy of Sciences of the United States of America·K PodsypaninaR Parsons
Aug 16, 2001·Proceedings of the National Academy of Sciences of the United States of America·M S NeshatC L Sawyers
Feb 19, 2002·Cancer Letters·Bozena KonopkaMarian Goluda
Jun 28, 2002·Cancer Cell·Brian J Druker
Apr 3, 2003·Nature Reviews. Cancer·Mace L RothenbergDavid H Johnson
Aug 12, 2003·Nature Reviews. Drug Discovery·Bruce BoothPhilip Ma
Oct 23, 2003·JAMA : the Journal of the American Medical Association·Mark G KrisAndrea C Kay
Nov 26, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeremy N RichHenry S Friedman
Dec 6, 2003·The Oncologist·Philip S ScheinStephen Carter
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Udo VanhoeferJosé Baselga
May 1, 2004·The New England Journal of Medicine·Thomas J LynchDaniel A Haber
May 1, 2004·Science·J Guillermo PaezMatthew Meyerson
Citations
Apr 27, 2010·Analytical and Bioanalytical Chemistry·Donald Wlodkowic, Jonathan M Cooper
Jan 3, 2012·Cancer Chemotherapy and Pharmacology·Jian-Feng LuYu-Nien Sun
Nov 8, 2008·Nature Reviews. Drug Discovery·Avi Ashkenazi
May 24, 2011·World Journal of Clinical Oncology·Donald Wlodkowic, Zbigniew Darzynkiewicz
May 15, 2010·Expert Review of Molecular Diagnostics·Donald Wlodkowic, Jonathan M Cooper
Apr 1, 2007·Expert Opinion on Drug Discovery·Allen D Roses
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott KopetzCathy Eng
Oct 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz-Josef LenzEric K Rowinsky
Jun 14, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric K Rowinsky
Jan 1, 2005·Current Opinion in Oncology·Eric K Rowinsky
Aug 6, 2019·Stem Cells·Sanam L Kavari, Khalid Shah
Mar 4, 2011·Clinical Pharmacology and Therapeutics·A D Ricart